Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 7849

1.

Does patient age influence anti-cancer immunity?

Pawelec G.

Semin Immunopathol. 2018 Jul 13. doi: 10.1007/s00281-018-0697-6. [Epub ahead of print] Review.

PMID:
30006738
2.

HIV-specific CD4+Th17 cells from HIV infected long-term non-progressors exhibit lower CTLA-4 expression and reduced apoptosis.

Saxena V, Patil A, Tayde R, Bichare S, Chinchkar V, Bagul R, Godbole S, Thakar M.

Immunobiology. 2018 Jul 6. pii: S0171-2985(18)30049-4. doi: 10.1016/j.imbio.2018.07.011. [Epub ahead of print]

PMID:
30005971
3.

[Immuno-Oncology: A Brief Overview].

Kobold S, Krackhardt A, Schlösser H, Wolf D.

Dtsch Med Wochenschr. 2018 Jul;143(14):1006-1013. doi: 10.1055/a-0623-9147. Epub 2018 Jul 13. German.

PMID:
30005434
4.

CXCR5+ CD8 T cells displayed higher activation potential despite high PD-1 expression, in tumor-involved lymph nodes from patients with thyroid cancer.

Zhou Y, Guo L, Sun H, Xu J, Ba T.

Int Immunopharmacol. 2018 Jul 9;62:114-119. doi: 10.1016/j.intimp.2018.07.002. [Epub ahead of print]

PMID:
30005226
5.

Nivolumab-induced systemic vasculitis.

Kang A, Yuen M, Lee DJ.

JAAD Case Rep. 2018 Jun 23;4(6):606-608. doi: 10.1016/j.jdcr.2018.03.013. eCollection 2018 Jul. No abstract available.

PMID:
30003129
6.

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.

Buder-Bakhaya K, Hassel JC.

Front Immunol. 2018 Jun 28;9:1474. doi: 10.3389/fimmu.2018.01474. eCollection 2018. Review.

PMID:
30002656
7.

Abatacept.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

8.

Belatacept.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

9.

Ipilimumab.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

10.

Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma.

Specenier P, Vermorken JB.

Expert Rev Anticancer Ther. 2018 Jul 12. doi: 10.1080/14737140.2018.1493925. [Epub ahead of print]

PMID:
29999437
11.

Bispecific antibodies in cancer immunotherapy.

Dahlén E, Veitonmäki N, Norlén P.

Ther Adv Vaccines Immunother. 2018 Feb;6(1):3-17. doi: 10.1177/2515135518763280. Epub 2018 Mar 28. Review.

PMID:
29998217
12.

Molecular Mechanisms of T Cells Activation by Dendritic Cells in Autoimmune Diseases.

Tai Y, Wang Q, Korner H, Zhang L, Wei W.

Front Pharmacol. 2018 Jun 26;9:642. doi: 10.3389/fphar.2018.00642. eCollection 2018. Review.

PMID:
29997500
13.

CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients.

Goltz D, Gevensleben H, Vogt TJ, Dietrich J, Golletz C, Bootz F, Kristiansen G, Landsberg J, Dietrich D.

JCI Insight. 2018 Jul 12;3(13). pii: 96793. doi: 10.1172/jci.insight.96793. [Epub ahead of print]

PMID:
29997292
14.

Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells.

Sawaf M, Fauny JD, Felten R, Sagez F, Gottenberg JE, Dumortier H, Monneaux F.

JCI Insight. 2018 Jul 12;3(13). pii: 99711. doi: 10.1172/jci.insight.99711. [Epub ahead of print]

PMID:
29997289
15.

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM.

JCI Insight. 2018 Jul 12;3(13). pii: 122092. doi: 10.1172/jci.insight.122092. [Epub ahead of print]

PMID:
29997287
16.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

PMID:
29996914
17.

A meta-analysis of the association between CTLA-4 genetic polymorphism and susceptibility of asthma.

Zheng Y, Wang H, Luo L, Liao L, You L, Wang J, Li Q.

Medicine (Baltimore). 2018 Jul;97(28):e11380. doi: 10.1097/MD.0000000000011380.

18.

Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review.

Babey H, Quéré G, Descourt R, Le Calloch R, Lanfranco L, Nousbaum JB, Cornec D, Tison A, Chouaid C.

Expert Rev Anticancer Ther. 2018 Jul 11. doi: 10.1080/14737140.2018.1499468. [Epub ahead of print]

PMID:
29995451
19.

Recent developments with immunotherapy for hepatocellular carcinoma.

Waidmann O.

Expert Opin Biol Ther. 2018 Jul 11. doi: 10.1080/14712598.2018.1499722. [Epub ahead of print]

PMID:
29995439
20.

Association of CD28 and CTLA4 haplotypes with susceptibility to primary Sjögren's syndrome in Mexican population.

López-Villalobos EF, Carrillo-Ballesteros FJ, Muñoz-Valle JF, Palafox-Sánchez CA, Valle Y, Orozco-Barocio G, Oregon-Romero E.

J Clin Lab Anal. 2018 Jul 10:e22620. doi: 10.1002/jcla.22620. [Epub ahead of print]

PMID:
29992636

Supplemental Content

Loading ...
Support Center